Zhonghua yi xue za zhi · 2009
[Serum proteomics profiling for diagnosis of myasthenia gravis].
Контролируемое клиническое исследованиеАннотация на английскомСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Guo-Yong, Pang Jing-Zhuo, Cheng Chao, Lu Jian-Jun, Ma Jun, Gu Yong, Zhong Fu-Tian, Luo Hong-He
Аннотация
OBJECTIVE: To identify the significant protein peaks and establish the diagnostic model of myasthenia gravis (MG) by serum proteomics profiling analysis.
METHODS: The serum samples from 56 MG patients and 16 healthy controls were detected by the technology of surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS). The differentially expressed protein peaks were identified to establish a MG diagnostic model. And preliminary validation was performed.
RESULTS: Thirty-eight specific protein peaks with significant differences were found in the serum protein pattern of 56 MG patients and 16 healthy controls. Systemic optimization identified 2 protein peaks of M4168.94 and M1122.57. And they were used to build the MG diagnostic model of differentiating 56 cases from 16 controls.
CONCLUSION: The serum protein profiling can be a novel, effective and sensitive tool to screen for MG-related protein peaks and establish a diagnostic model.
METHODS: The serum samples from 56 MG patients and 16 healthy controls were detected by the technology of surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS). The differentially expressed protein peaks were identified to establish a MG diagnostic model. And preliminary validation was performed.
RESULTS: Thirty-eight specific protein peaks with significant differences were found in the serum protein pattern of 56 MG patients and 16 healthy controls. Systemic optimization identified 2 protein peaks of M4168.94 and M1122.57. And they were used to build the MG diagnostic model of differentiating 56 cases from 16 controls.
CONCLUSION: The serum protein profiling can be a novel, effective and sensitive tool to screen for MG-related protein peaks and establish a diagnostic model.